2026-05-07 · medications, zepbound, tirzepatide, glp-1

Zepbound for Weight Loss

Who this is for / not for

Good fit if:

• You are an adult with obesity (BMI 30 or higher), or overweight (BMI 27 or higher) with a weight-related condition such as type 2 diabetes, high blood pressure, or high cholesterol.
• You want a weekly injectable option with strong appetite and weight effects and can stick with dose titration.
• You are ready to pair medication with nutrition, activity, and ongoing clinician follow-up.

Not a fit if:

• You have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
• You have a history of pancreatitis, severe gastrointestinal disease, or current severe gastroparesis without specialist clearance.
• You are pregnant, breastfeeding, or planning pregnancy in the near term.

What Zepbound is

Zepbound is the U.S. brand name for tirzepatide when prescribed for chronic weight management. Tirzepatide is the same molecule sold as Mounjaro for type 2 diabetes. The FDA approved Zepbound in late 2023 for adults with obesity, or adults who are overweight and have at least one weight-related condition, as an addition to a reduced-calorie diet and increased physical activity.

Tirzepatide is a once-weekly, dual GIP and GLP-1 receptor agonist. In plain terms, it is a single injection that acts on two gut-hormone pathways involved in appetite and blood sugar control. For a broader view of this drug class, see the GLP-1 weight loss overview. For information on the molecule itself, see tirzepatide for weight loss.

How it works

Tirzepatide activates receptors for two hormones your gut normally releases after meals: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Acting on both pathways:

• Slows stomach emptying, so meals feel more filling for longer.
• Reduces appetite and food-related cravings signals in the brain.
• Improves insulin response and blood sugar control after meals.

These effects combine to reduce calorie intake without the hunger spikes that usually follow aggressive dieting. Zepbound works best alongside structured nutrition and physical activity habits; it is not a substitute for lifestyle change.

Expected weight loss

Zepbound’s expected results come mainly from the SURMOUNT-1 trial, a 72-week randomized study in adults with obesity who did not have diabetes.

Average total body weight loss from SURMOUNT-1:

• About 15% at the 5 mg weekly dose.
• About 19.5% at the 10 mg weekly dose.
• About 20.9% at the 15 mg weekly dose.
• About 3.1% with placebo.

In SURMOUNT-2, which studied adults with overweight or obesity and type 2 diabetes, average weight loss at 72 weeks was lower (roughly 12 to 15 percent), which is typical for this population. Individual results vary. Most people see early appetite changes in the first weeks, with steady weight loss accumulating over several months. As with other GLP-1 class drugs, stopping Zepbound is associated with gradual weight regain unless a maintenance plan is in place.

Dosing and administration

Zepbound is a subcutaneous injection given once a week, on the same day each week, in the stomach, thigh, or upper arm. It is supplied as a single-dose pen or vial.

Typical titration schedule:

• Start at 2.5 mg once weekly for 4 weeks (a starter dose meant to reduce side effects, not intended for long-term weight management).
• Increase to 5 mg once weekly, and after at least 4 weeks at each step, continue stepping up in 2.5 mg increments as tolerated.
• Maintenance doses are 5 mg, 10 mg, or 15 mg weekly, chosen based on tolerability and response.

If a dose is missed, the manufacturer advises taking it within 4 days; otherwise, skip the missed dose and take the next scheduled dose. Do not double up. Store pens refrigerated when unopened, and follow pen-specific room-temperature limits.

Side effects and safety

Most side effects are gastrointestinal, dose-related, and typically improve after the body adjusts to each new dose.

Common side effects:

• Nausea, vomiting, diarrhea, constipation.
• Decreased appetite, abdominal pain, reflux, burping.
• Injection-site reactions, fatigue, mild hair shedding.

Serious or less common risks:

• Boxed warning for thyroid C-cell tumors based on rodent data; avoid in people with a personal or family history of medullary thyroid carcinoma or MEN2.
• Pancreatitis: stop the drug and seek care for persistent severe abdominal pain.
• Gallbladder disease, including gallstones and cholecystitis.
• Acute kidney injury, usually linked to dehydration from vomiting or diarrhea.
• Hypoglycemia, particularly when Zepbound is combined with insulin or sulfonylureas.
• Diabetic retinopathy complications in some people with type 2 diabetes.
• Suicidal thoughts or mood changes have been reported across the GLP-1 class; postmarketing surveillance is ongoing.

For broader safety context across this drug class, see weight loss drug safety.

Cost and access

In the U.S., Zepbound’s list price is roughly $1,060 to $1,100 per month for a one-month supply of weekly pens, depending on pharmacy. Actual out-of-pocket cost depends on insurance.

Typical access points:

• Commercial insurance: Coverage for weight-loss drugs varies by plan. Prior authorization is common and often requires documentation of BMI, prior weight-loss attempts, and related conditions. For how Zepbound fits among other approved options, see our overview of prescription weight loss medications.
• Medicare: As of the time of writing, Medicare Part D is not permitted to cover medications used strictly for weight loss, so Zepbound is typically not covered for weight management under Medicare. Coverage rules may change.
• Manufacturer support: Eli Lilly has offered a Zepbound savings card for eligible commercial plans and a self-pay single-dose vial option at reduced prices for some doses.
• Compounded tirzepatide: Compounded versions are not FDA-approved, have not been reviewed for safety, efficacy, or quality, and have been the subject of FDA safety communications. Compounding is only allowed under narrow circumstances, and product consistency can vary.

Plan for recurring monthly costs for as long as you remain on therapy, plus clinician visits and any labs your prescriber orders.

Zepbound vs Wegovy (brief)

Wegovy is semaglutide dosed for chronic weight management; Zepbound is tirzepatide dosed for chronic weight management. Both are once-weekly injections with FDA approval in similar populations, but they are different molecules with different mechanisms: Wegovy targets GLP-1 only, while Zepbound targets both GIP and GLP-1. Across available trial data, average weight loss tends to be higher with Zepbound, though Wegovy has longer real-world safety experience and distinct cardiovascular outcome data. Side-effect profiles are broadly similar. The better choice depends on medical history, insurance coverage, tolerability, and clinician judgment. For a deeper comparison of the molecules, see semaglutide vs tirzepatide and semaglutide for weight loss. For the brand-vs-brand semaglutide question, see our Ozempic vs Wegovy breakdown.

Frequently asked questions

Practical next steps

This week

• Confirm whether your BMI and conditions meet FDA criteria for Zepbound, and whether your insurance lists it on the formulary.
• Ask your prescriber about a titration plan, a consistent injection day, and how to reach them for side-effect questions.
• Start a simple log of weight, appetite, and any GI symptoms so you have trend data for follow-ups.

What to track

• Weekly weight trend and appetite changes.
• GI symptoms (nausea, vomiting, diarrhea, constipation) and hydration.
• Protein intake, resistance training sessions, and sleep.

How to know it is working

• Appetite feels lower and portion sizes are easier to manage.
• Weight loss accumulates steadily over months, not pounds in a single week.
• Side effects peak briefly after each dose step, then ease.

How this article was researched

This article draws on the SURMOUNT-1 and SURMOUNT-2 randomized trials published in the New England Journal of Medicine, the FDA approval announcement for tirzepatide in chronic weight management, and the FDA prescribing information for Zepbound. Safety summaries reflect labeled warnings and postmarketing communications from the FDA. Cost and coverage details reflect publicly posted manufacturer and payer information at the time of writing.